Title: Medical treatment of Cushing disease: new targets, new hope.

Journal: Endocrinology and metabolism clinics of North America20150301

Title: Involvement of bone morphogenetic protein activity in somatostatin actions on ovarian steroidogenesis.

Journal: The Journal of steroid biochemistry and molecular biology20130301

Title: Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.

Journal: Endocrine20121001

Title: Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors.

Journal: Endocrine-related cancer20121001

Title: Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.

Journal: Endocrine-related cancer20121001

Title: Pasireotide (SOM230) protects the retina in animal models of ischemia induced retinopathies.

Journal: Experimental eye research20121001

Title: Medical management of Cushing's disease: what is the future?

Journal: Pituitary20120901

Title: Pasireotide.

Journal: Nature reviews. Drug discovery20120801

Title: Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.

Journal: Journal of clinical pharmacology20120701

Title: Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.

Journal: European journal of endocrinology20120501

Title: The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy.

Journal: The Journal of clinical endocrinology and metabolism20120401

Title: A 12-month phase 3 study of pasireotide in Cushing's disease.

Journal: The New England journal of medicine20120308

Title: Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.

Journal: Clinical therapeutics20120301

Title: Advances in medical therapies for Cushing's syndrome.

Journal: Discovery medicine20120201

Title: [Endocrinology].

Journal: Revue medicale suisse20120111

Title: Effects of somatostatin analogs on glucose homeostasis in rats.

Journal: The Journal of endocrinology20120101

Title: A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.

Journal: Drug design, development and therapy20120101

Title: A transplantable phosphorylation probe for direct assessment of G protein-coupled receptor activation.

Journal: PloS one20120101

Title: SOM230 in Cushing's disease complicated by poorly controlled diabetes mellitus.

Journal: Journal of endocrinological investigation20111001

Title: Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis.

Journal: Arthritis and rheumatism20110801

Title: SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts.

Journal: Cancer biology & therapy20110701

Title: Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.

Journal: Future oncology (London, England)20110701

Title: Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells.

Journal: Journal of endocrinological investigation20110601

Title: Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists.

Journal: Molecular endocrinology (Baltimore, Md.)20110601

Title: [Role of somatostatin receptor ligands in the treatment of acromegaly--literature review].

Journal: Orvosi hetilap20110501

Title: Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing's syndrome.

Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme20110401

Title: Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia.

Journal: Pituitary20110301

Title: Pituitary tumors in 2010: a new therapeutic era for pituitary tumors.

Journal: Nature reviews. Endocrinology20110201

Title: Prevention of breast cancer: the case for studying inhibition of IGF-1 actions.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology20110101

Title: Effect of SOM230 (pasireotide) on corticotropic cells: action in dogs with Cushing's disease.

Journal: Neuroendocrinology20110101

Title: SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases.

Journal: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association20101101

Title: Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.

Journal: Cancer treatment reviews20101101

Title: Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model.

Journal: European journal of pharmacology20101010

Title: Pharmacological management of acromegaly: a current perspective.

Journal: Neurosurgical focus20101001

Title: Comment on 'Non-surgical treatment of hormone-secreting pituitary tumors'.

Journal: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia20100901

Title: Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.

Journal: The Journal of clinical endocrinology and metabolism20100601

Title: Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

Journal: The New England journal of medicine20100513

Title: Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.

Journal: The Journal of clinical endocrinology and metabolism20100201

Title: Twelve years of the Spanish acromegaly registry: a historical view of acromegaly management in Spain.

Journal: Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion20100201

Title: Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.

Journal: Molecular endocrinology (Baltimore, Md.)20100101

Title: ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines.

Journal: Neuroendocrinology20100101

Title: Novel medical therapies for pituitary tumors.

Journal: Frontiers of hormone research20100101

Title: Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.

Journal: Neuroendocrinology20100101

Title: Somatostatin and dopamine receptors.

Journal: Tumori20100101

Title: [Treatment of pituitary adenomas].

Journal: Orvosi hetilap20090927

Title: The somatostatin analog SOM230 (pasireotide) ameliorates injury of the intestinal mucosa and increases survival after total-body irradiation by inhibiting exocrine pancreatic secretion.

Journal: Radiation research20090601

Title: Backbone conformations and side chain flexibility of two somatostatin mimics investigated by molecular dynamics simulations.

Journal: Proteins20090515

Title: Current therapy and drug pipeline for the treatment of patients with acromegaly.

Journal: Advances in therapy20090401

Title: [The medical management of Cushing's syndrome].

Journal: Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion20090401

Title: Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.

Journal: The Journal of clinical endocrinology and metabolism20090201

Title: Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies.

Journal: The Journal of clinical endocrinology and metabolism20090201

Title: Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

Journal: The Journal of clinical endocrinology and metabolism20090101

Title: Impact of Octreotide and SOM-230 on liver metastasis and hepatic lipidperoxidation in ductal pancreatic adenocarcinoma in Syrian Hamster.

Journal: Clinical & experimental metastasis20090101

Title: Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation.

Journal: The Journal of international medical research20090101

Title: Modulation of the neuronal response to ischaemia by somatostatin analogues in wild-type and knock-out mouse retinas.

Journal: Journal of neurochemistry20080901

Title: Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells.

Journal: Journal of molecular endocrinology20080601

Title: Pasireotide (SOM230): development, mechanism of action and potential applications.

Journal: Molecular and cellular endocrinology20080514

Title: Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.

Journal: European journal of endocrinology20080501

Title: Pituitary-targeted medical therapy of Cushing's disease.

Journal: Expert opinion on investigational drugs20080501

Title: [Management of patients with neuroendocrine tumors of the esophagus, stomach, and duodenum].

Journal: Nihon Geka Gakkai zasshi20080501

Title: Preclinical evidences suggest new treatment options for endocrine disorders: Pasireotide (SOM230) and Everolimus (RAD001).

Journal: Annales d'endocrinologie20080401

Title: Modulation of expression of somatostatin receptor subtypes in Graves' ophthalmopathy orbits: relevance to novel analogs.

Journal: American journal of physiology. Endocrinology and metabolism20071201

Title: Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease.

Journal: IDrugs : the investigational drugs journal20071201

Title: Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary.

Journal: Endocrinology20070601

Title: SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20070501

Title: Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues.

Journal: Regulatory peptides20070110

Title: Inhibitory effect of pasireotide and octreotide on lymphocyte activation.

Journal: Journal of neuroimmunology20070101

Title: Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727.

Journal: Anticancer research20070101

Title: Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.

Journal: European journal of endocrinology20060801

Title: SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?

Journal: Molecular endocrinology (Baltimore, Md.)20060201

Title: Gateways to clinical trials.

Journal: Methods and findings in experimental and clinical pharmacology20051201

Title: Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats.

Journal: European journal of endocrinology20050901

Title: Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.

Journal: American journal of physiology. Endocrinology and metabolism20050801

Title: The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.

Journal: Clinical endocrinology20050801

Title: Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.

Journal: Clinical pharmacology and therapeutics20050701

Title: Regulation of ghrelin secretion by somatostatin analogs in rats.

Journal: European journal of endocrinology20050601

Title: Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium.

Journal: British journal of cancer20050425

Title: The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.

Journal: European journal of endocrinology20050401

Title: Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance.

Journal: Treatments in endocrinology20050101

Title: Primary therapy for acromegaly with somatostatin analogs and a discussion of novel peptide analogs.

Journal: Reviews in endocrine & metabolic disorders20050101

Title: Medicinal chemistry of somatostatin analogs leading to the DTPA and DOTA conjugates of the multi-receptor-ligand SOM230.